<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35475030</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2452-199X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>19</Volume>
            <PubDate>
              <Year>2023</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Bioactive materials</Title>
          <ISOAbbreviation>Bioact Mater</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Reactive oxygen species (ROS)-responsive size-reducible nanoassemblies for deeper atherosclerotic plaque penetration and enhanced macrophage-targeted drug delivery.</ArticleTitle>
        <Pagination>
          <StartPage>115</StartPage>
          <EndPage>126</EndPage>
          <MedlinePgn>115-126</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bioactmat.2022.03.041</ELocationID>
        <Abstract>
          <AbstractText>Nanoparticle-based therapeutics represent potential strategies for treating atherosclerosis; however, the complex plaque microenvironment poses a barrier for nanoparticles to target the dysfunctional cells. Here, we report reactive oxygen species (ROS)-responsive and size-reducible nanoassemblies, formed by multivalent host-guest interactions between β-cyclodextrins (β-CD)-anchored discoidal recombinant high-density lipoprotein (NP<sup>3</sup> <sub>ST</sub>) and hyaluronic acid-ferrocene (HA-Fc) conjugates. The HA-Fc/NP<sup>3</sup> <sub>ST</sub> nanoassemblies have extended blood circulation time, specifically accumulate in atherosclerotic plaque mediated by the HA receptors CD44 highly expressed in injured endothelium, rapidly disassemble in response to excess ROS in the intimal and release smaller NP<sup>3</sup> <sub>ST</sub>, allowing for further plaque penetration, macrophage-targeted cholesterol efflux and drug delivery. <i>In vivo</i> pharmacodynamicses in atherosclerotic mice shows that HA-Fc/NP<sup>3</sup> <sub>ST</sub> reduces plaque size by 53%, plaque lipid deposition by 63%, plaque macrophage content by 62% and local inflammatory factor level by 64% compared to the saline group. Meanwhile, HA-Fc/NP<sup>3</sup> <sub>ST</sub> alleviates systemic inflammation characterized by reduced serum inflammatory factor levels. Collectively, HA-Fc/NP<sup>3</sup> <sub>ST</sub> nanoassemblies with ROS-responsive and size-reducible properties exhibit a deeper penetration in atherosclerotic plaque and enhanced macrophage targeting ability, thus exerting effective cholesterol efflux and drug delivery for atherosclerosis therapy.</AbstractText>
          <CopyrightInformation>© 2022 The Authors.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Jianhua</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, China Pharmaceutical University, Nanjing, Jiangsu, 210009, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Wenli</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, China Pharmaceutical University, Nanjing, Jiangsu, 210009, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Xiaoju</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, China Pharmaceutical University, Nanjing, Jiangsu, 210009, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Fengfei</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, China Pharmaceutical University, Nanjing, Jiangsu, 210009, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zou</LastName>
            <ForeName>Jiahui</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, China Pharmaceutical University, Nanjing, Jiangsu, 210009, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Qiqi</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, China Pharmaceutical University, Nanjing, Jiangsu, 210009, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Yi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>School of Biomedical Engineering, Sun Yat-sen University, Shenzhen, 518107, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Hongliang</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Bioelectronics, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 210096, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Hu</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Linda and Bipin Doshi Department of Chemical and Biochemical Engineering, Missouri University of Science and Technology, Rolla, MO, 65401, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Jianping</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, China Pharmaceutical University, Nanjing, Jiangsu, 210009, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Bioact Mater</MedlineTA>
        <NlmUniqueID>101685294</NlmUniqueID>
        <ISSNLinking>2452-199X</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Atherosclerosis</Keyword>
        <Keyword MajorTopicYN="N">Macrophage</Keyword>
        <Keyword MajorTopicYN="N">Reactive oxygen species</Keyword>
        <Keyword MajorTopicYN="N">Recombinant high-density lipoprotein</Keyword>
        <Keyword MajorTopicYN="N">Size-reducible nanoassemblies</Keyword>
      </KeywordList>
      <CoiStatement>There are no conflicts of interest to declare.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>19</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35475030</ArticleId>
        <ArticleId IdType="pmc">PMC9010555</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bioactmat.2022.03.041</ArticleId>
        <ArticleId IdType="pii">S2452-199X(22)00157-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kaptoge S., Pennells L., De Bacquer D., Cooney M.T., Kavousi M., Stevens G., Riley L.M., Savin S., Khan T., Altay S. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Global Health. 2019;7(10):e1332–e1345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7025029</ArticleId>
            <ArticleId IdType="pubmed">31488387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524–533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33883728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolf D., Ley K. Immunity and inflammation in atherosclerosis. Circ. Res. 2019;124(2):315–327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore K.J., Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145(3):341–355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3111065</ArticleId>
            <ArticleId IdType="pubmed">21529710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Libby P., Ridker P.M., Hansson G.R.K. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21593864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barrett T.J. Macrophages in atherosclerosis regression. Arterioscler. Thromb. Vasc. Biol. 2020;40(1):20–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6946104</ArticleId>
            <ArticleId IdType="pubmed">31722535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber C., Noels H. Atherosclerosis: Current pathogenesis and therapeutic options. Nat. Med. 2011;17(11):1410–1422.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22064431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zang X., Cheng M., Zhang X., Chen X. Targeting macrophages using nanoparticles: a potential therapeutic strategy for atherosclerosis. J. Mater. Chem. B. 2021;9(15):3284–3294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33881414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li C., Dou Y., Chen Y., Qi Y., Li L., Han S., Jin T., Guo J., Chen J., Zhang J. Site‐specific microRNA‐33 antagonism by pH‐responsive nanotherapies for treatment of atherosclerosis via regulating cholesterol efflux and adaptive immunity. Adv. Funct. Mater. 2020;30(42):2002131.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang J., Zu Y., Dhanasekara C.S., Li J., Wu D., Fan Z., Wang S. Detection and treatment of atherosclerosis using nanoparticles. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2017;9(1):e1412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5133203</ArticleId>
            <ArticleId IdType="pubmed">27241794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matoba T., Koga J.-i., Nakano K., Egashira K., Tsutsui H. Nanoparticle-mediated drug delivery system for atherosclerotic cardiovascular disease. J. Cardiol. 2017;70(3):206–211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28416142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L., Jiang Z., Akakuru O., Yang L., Li J., Ma S., Wu A. Recent progress in the detection and treatment of atherosclerosis by nanoparticles. Mater. Today Chem. 2020;17:100280.</Citation>
        </Reference>
        <Reference>
          <Citation>Yuan F., Quan L.D., Cui L., Goldring S.R., Wang D. Development of macromolecular prodrug for rheumatoid arthritis. Adv. Drug Deliv. Rev. 2012;64(12):1205–1219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3572768</ArticleId>
            <ArticleId IdType="pubmed">22433784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu G., Wei W., Zhang J., Nie W., Yuan L., Huang Y., Zuo L., Huang L., Xi X., Xie H.-Y. A self-driven bioinspired nanovehicle by leukocyte membrane-hitchhiking for early detection and treatment of atherosclerosis. Biomaterials. 2020;250:119963.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32334199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newby A.C., Zaltsman A.B. Fibrous cap formation or destruction—the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation. Cardiovasc. Res. 1999;41(2):345–360.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10341834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martos-Rodríguez C.J., Albarrán-Juárez J., Morales-Cano D., Caballero A., MacGrogan D., de la Pompa J.L., Carramolino L., Bentzon J.F. Fibrous caps in atherosclerosis form by notch-dependent mechanisms Common to arterial media development, arteriosclerosis, thrombosis, and vascular biology. ATVBAHA. 2021;120:315627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34261328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J., Ke W., Li H., Zha Z., Han Y., Ge Z. Endogenous stimuli‐sensitive multistage polymeric micelleplex anticancer drug delivery system for efficient tumor penetration and cellular internalization. Adv. Healthcare Mater. 2015;4(15):2206–2219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26346421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Z., Liu Y., Zhang M., Li C., Yang R., Li J., Qian C., Sun M. Size switchable nanoclusters fueled by extracellular ATP for promoting deep penetration and MRI‐guided tumor photothermal therapy. Adv. Funct. Mater. 2019;29(39):1904144.</Citation>
        </Reference>
        <Reference>
          <Citation>Taniguchi R., Miura Y., Koyama H., Chida T., Anraku Y., Kishimura A., Shigematsu K., Kataoka K., Watanabe T. Adequately-sized nanocarriers allow sustained targeted drug delivery to neointimal lesions in rat arteries. Mol. Pharm. 2016:2108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27183493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aniruddha Roy, Mark J., Ernsting Mami Murakami. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J. Contr. Release Off. J. Controlled Release Soc. 2013;172(3):782–794.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3891171</ArticleId>
            <ArticleId IdType="pubmed">24075927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kattoor A.J., Pothineni N.V.K., Palagiri D., Mehta J.L. Oxidative stress in atherosclerosis. Curr. Atherosclerosis Rep. 2017;19(11):1–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28921056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang X., Li Y., Li Y., Ren X., Zhang X., Hu D., Gao Y., Xing Y., Shang H. Oxidative stress-mediated atherosclerosis: mechanisms and therapies. Front. Physiol. 2017;8:600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5572357</ArticleId>
            <ArticleId IdType="pubmed">28878685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Förstermann U., Xia N., Li H. Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circ. Res. 2017;120(4):713–735.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28209797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Förstermann U. Oxidative stress in vascular disease: Causes, defense mechanisms and potential therapies. Nat. Clin. Pract. Cardiovasc. Med. 2008;5(6):338–349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18461048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Q., He C., Xiao C., Chen X. Reactive oxygen species (ROS) responsive polymers for biomedical applications. Macromol. Biosci. 2016;16(5):635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26891447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim H., Kim Y., Kim I.H., Kim K., Choi Y. ROS-responsive activatable photosensitizing agent for imaging and photodynamic therapy of activated macrophages. Theranostics. 2014;4(1):1–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3881223</ArticleId>
            <ArticleId IdType="pubmed">24396511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>S.H. Lee, M.K. Gupta, J.B. Bang, H. Bae, H.-J. Sung, Current progress in reactive oxygen species (ROS)-Responsive materials for biomedical applications, Advanced Healthcare Materials 2(6) 908-915.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4146500</ArticleId>
            <ArticleId IdType="pubmed">25136729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>S. Joshi-Barr, C. de Gracia Lux, E. Mahmoud, A. Almutairi, Exploiting oxidative microenvironments in the body as triggers for drug delivery systems, Antioxidants Redox Signal. 21(5) 730-754.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4098119</ArticleId>
            <ArticleId IdType="pubmed">24328819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Y. Ochi, M. Suzuki, T. Imaoka, M. Murata, H. Nishihara, Y. Einaga, K. Yamamoto, Controlled storage of ferrocene derivatives as redox-active molecules in dendrimers, J. Am. Chem. Soc. 132(14) 5061-5069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20302350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>E.R. Dionne, T. Sultana, L.L. Norman, V. Toader, A. Badia, Redox-induced ion pairing of anionic surfactants with ferrocene-terminated self-assembled monolayers: Faradaic electrochemistry and surfactant aggregation at the monolayer/liquid interface, J. Am. Chem. Soc. 135(46) 17457-17468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24191744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang J., Lobatto M.E., Hassing L., Van Der Staay S., Van Rijs S.M., Calcagno C., Braza M.S., Baxter S., Fay F., Sanchez-Gaytan B.L. Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation. Sci. Adv. 2015;1(3)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4539616</ArticleId>
            <ArticleId IdType="pubmed">26295063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koushki K., Shahbaz S.K., Mashayekhi K., Sadeghi M., Zayeri Z.D., Taba M.Y., Banach M., Al-Rasadi K., Johnston T.P., Sahebkar A. Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways. Clin. Rev. Allergy Immunol. 2021;60(2):175–199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7985098</ArticleId>
            <ArticleId IdType="pubmed">32378144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Argmann C.A., Edwards J.Y., Sawyez C.G., O’Neil C.H., Hegele R.A., Pickering J.G., Huff M.W. Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition. J. Biol. Chem. 2005;280(23):22212–22221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15817453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Q., He J., Xu F., Huang X., Wang Y., Zhang W., Liu J.  Biomaterials Science; 2021. Supramolecular Copolymer Modified Statins-Loaded Discoidal rHDLs for Atherosclerotic Anti-inflammatory Therapy by Cholesterol Efflux and M2 Macrophage Polarization.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34346410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He J., Yang Y., Zhou X., Zhang W., Liu J. A shuttle/sink model composing of β-cyclodextrin and simvastatin-loaded discoidal reconstituted high-density lipoprotein for enhanced cholesterol efflux and drug uptake in macrophage/foam cells. J. Mater. Chem. B. 2020;8(7):1496–1506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31999290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Namgung R., Lee Y.M., Kim J., Jang Y., Lee B.-H., Kim I.-S., Sokkar P., Rhee Y.M., Hoffman A.S., Kim W.J. Poly-cyclodextrin and poly-paclitaxel nano-assembly for anticancer therapy. Nat. Commun. 2014;5(1):1–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24805848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeon H., Kim J., Lee Y.M., Kim J., Choi H.W., Lee J., Park H., Kang Y., Kim I.-S., Lee B.-H. Poly-paclitaxel/cyclodextrin-SPION nano-assembly for magnetically guided drug delivery system. J. Contr. Release. 2016;231:68–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26780174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee G.Y., Kim J.-H., Choi K.Y., Yoon H.Y., Kim K., Kwon I.C., Choi K., Lee B.-H., Park J.H., Kim I.-S. Hyaluronic acid nanoparticles for active targeting atherosclerosis. Biomaterials. 2015;53:341–348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25890732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu L., He H., Zhang M., Zhang S., Zhang W., Liu J. Hyaluronic acid-decorated reconstituted high density lipoprotein targeting atherosclerotic lesions. Biomaterials. 2014;35(27):8002–8014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24947229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hou X., Lin H., Zhou X., Cheng Z., Li Y., Liu X., Zhao F., Zhu Y., Zhang P., Chen D. Novel dual ROS-sensitive and CD44 receptor targeting nanomicelles based on oligomeric hyaluronic acid for the efficient therapy of atherosclerosis. Carbohydr. Polym. 2020;232:115787.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31952595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saravanakumar G., Kim J., Kim W.J. Reactive‐oxygen‐species‐responsive drug delivery systems: promises and challenges. Adv. Sci. 2017;4(1):1600124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5238745</ArticleId>
            <ArticleId IdType="pubmed">28105390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Na Y., Lee J.S., Woo J., Ahn S., Lee E., Choi W.I., Sung D. Reactive oxygen species (ROS)-responsive ferrocene-polymer-based nanoparticles for controlled release of drugs. J. Mater. Chem. B. 2020;8(9):1906–1913.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32043093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W., Ji W., Jia J., Liang C., Liu J. A simple method to extract whole apolipoproteins for the preparation of discoidal recombined high density lipoproteins as bionic nanocarriers for drug delivery. J. Pharm. Pharmaceut. Sci. 2015;18(2):184–198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26158284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leif H. Selective extraction of lecithin:cholesterol acyltransferase (EC 2.3.1.43) from human plasma. J. Biochem. Biophys. Methods. 2002;52(1):63–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12121755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin R., Teixeira L.M., Dijkstra P.J., Van Blitterswijk C., Karperien M., Feijen J. Enzymatically-crosslinked injectable hydrogels based on biomimetic dextran–hyaluronic acid conjugates for cartilage tissue engineering. Biomaterials. 2010;31(11):3103–3113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20116847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu Y., Wang J., Li X., Zhao D., Sun J., Liu X. Self-assembly and emulsification of dopamine-modified hyaluronan. Carbohydr. Polym. 2015;123:72–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25843836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He H., Liu L., Bai H., Wang J., Zhang Y., Zhang W., Zhang M., Wu Z., Liu J. Arachidonic acid-modified lovastatin discoidal reconstituted high density lipoprotein markedly decreases the drug leakage during the remodeling behaviors induced by lecithin cholesterol acyltransferase. Pharmaceut. Res. 2014;31(7):1689–1709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24449440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W., He H., Liu J., Wang J., Zhang S., Zhang S., Wu Z. Pharmacokinetics and atherosclerotic lesions targeting effects of tanshinone IIA discoidal and spherical biomimetic high density lipoproteins. Biomaterials. 2013;34(1):306–319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23069716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murakami T., Michelagnoli S., Longhi R., Gianfranceschi G., Franceschini G. Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. Arterioscler. Thromb. Vasc. Biol. 1995;15(11):1819–1828.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7583561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou W., Liu W., Zou L., Liu W., Liu C., Liang R., Chen J. Storage stability and skin permeation of vitamin C liposomes improved by pectin coating. Colloids Surf. B Biointerfaces. 2014;117:330–337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24681045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yi Z., Hai G., Jianhua H., Cuiping J., Jing L., Wenli Z., Hu Y., Jianping L. Co-delivery of LOX-1 siRNA and statin to endothelial cells and macrophages in the atherosclerotic lesions by a dual-targeting core-shell nanoplatform: a dual cell therapy to regress plaques. J. Contr. Release. 2018;283:241–260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29885417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang L.Q., Wang T.Y., Webster T.J., Duan H.-J., Qiu J.Y., Zhao Z.M., Yin X.X., Zheng C.L. Intracellular disposition of chitosan nanoparticles in macrophages: intracellular uptake, exocytosis, and intercellular transport. Int. J. Nanomed. 2017;12:6383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5587219</ArticleId>
            <ArticleId IdType="pubmed">28919742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D'Autréaux B., Toledano M.B. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat. Rev. Mol. Cell Biol. 2007;8(10):813–824.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17848967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao C., Huang Q., Liu C., Kwong C.H.T., Wang R. Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines. Nat. Commun. 2020;11(1)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7251120</ArticleId>
            <ArticleId IdType="pubmed">32457361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Srinivasan B., Kolli A.R., Esch M.B., Abaci H.E., Shuler M.L., Hickman J.J. TEER measurement techniques for in vitro barrier model systems. J. Lab. Autom. 2015;20(2):107–126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4652793</ArticleId>
            <ArticleId IdType="pubmed">25586998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim Y., Lobatto M.E., Kawahara T., Chung B.L., Mieszawska A.J., Sanchez-Gaytan B.L., Fay F., Senders M.L., Calcagno C., Becraft J. Probing nanoparticle translocation across the permeable endothelium in experimental atherosclerosis. Proc. Natl. Acad. Sci. Unit. States Am. 2014;111(3):1078–1083.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3903216</ArticleId>
            <ArticleId IdType="pubmed">24395808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W., Li C., Baguley B.C., Zhou F., Zhou W., Shaw J.P., Wang Z., Wu Z., Liu J. Optimization of the formation of embedded multicellular spheroids of MCF-7 cells: how to reliably produce a biomimetic 3D model. Anal. Biochem. 2016;515:47–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27717854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin Y., Wu Z., Wu C., Zi Y., Chu X., Liu J., Zhang W. Size-adaptable and ligand (biotin)-sheddable nanocarriers equipped with avidin scavenging technology for deep tumor penetration and reduced toxicity. J. Contr. Release. 2020;320:142–158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31978442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shan W., Zhu X., Liu M., Li L., Zhong J., Sun W., Zhang Z., Huang Y. Overcoming the diffusion barrier of mucus and absorption barrier of epithelium by self-assembled nanoparticles for oral delivery of insulin. ACS Nano. 2015;9(3):2345–2356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25658958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ju C., Mo R., Xue J., Zhang L., Zhao Z., Xue L., Ping Q., Zhang C. Sequential intra‐intercellular nanoparticle delivery system for deep tumor penetration. Angew. Chem. 2014;126(24):6367–6372.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24740532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding Y., Liu J., Zhang Y., Li X., Ou H., Cheng T., Ma L., An Y., Liu J., Huang F., Liu Y., Shi L. A novel strategy based on a ligand-switchable nanoparticle delivery system for deep tumor penetration. Nanoscale Horizons. 2019;4:658–666.</Citation>
        </Reference>
        <Reference>
          <Citation>C. Jiang, Y. Zhao, Y. Yang, J. He, W. Zhang, J. Liu, Evaluation of the combined effect of recombinant high-density lipoprotein carrier and the encapsulated lovastatin in RAW264.7 macrophage cells based on the median-effect principle, Mol. Pharm. 15(3) 1017-1027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29382194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu J., Zhao Y., Zhou X., He J.H., Yang Y., Jiang C., Qi Z., Zhang W., Liu J. Biofunctional polymer–lipid hybrid high-density lipoprotein-mimicking nanoparticles loading anti-miR155 for combined antiatherogenic effects on macrophages. Biomacromolecules. 2017;18(8):2286–2295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28738148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang C., Qi Z., He W., Li Z., Tang Y., Wang Y., Huang Y., Zang H., Yang H., Liu J. Dynamically enhancing plaque targeting via a positive feedback loop using multifunctional biomimetic nanoparticles for plaque regression. J. Contr. Release. 2019;308:71–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31295543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu M., Shen S., Wen D., Li M., Li T., Chen X., Gu Z., Mo R. Hierarchical nanoassemblies-assisted combinational delivery of cytotoxic protein and antibiotic for cancer treatment. Nano Lett. 2018;18(4):2294–2303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29547698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y., Li L., Zhao W., Dou Y., An H., Tao H., Xu X., Jia Y., Lu S., Zhang J. Targeted therapy of atherosclerosis by a broad-spectrum reactive oxygen species scavenging nanoparticle with intrinsic anti-inflammatory activity. ACS Nano. 2018;12(9):8943–8960.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu X., Zeng Z., Chen J., Huang B., Guan Z., Huang Y., Huang Z., Zhao C. Tumor-targeted supramolecular catalytic nanoreactor for synergistic chemo/chemodynamic therapy via oxidative stress amplification and cascaded Fenton reaction. Chem. Eng. J. 2020;390:124628.</Citation>
        </Reference>
        <Reference>
          <Citation>Mittal M., Siddiqui M.R., Tran K., Reddy S.P., Malik A.B. Reactive oxygen species in inflammation and tissue injury. Antioxidants Redox Signal. 2014;20(7):1126–1167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3929010</ArticleId>
            <ArticleId IdType="pubmed">23991888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma B., Xu H., Zhuang W., Wang Y., Li G., Wang Y. ROS responsive nanoplatform with two‐photon AIE imaging for atherosclerosis diagnosis and “two‐pronged” therapy. Small. 2020;16(45):2003253.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33078569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma B., Xu H., Zhuang W., Wang Y., Li G., Wang Y. Reactive oxygen species responsive theranostic nanoplatform for two-photon aggregation-induced emission imaging and therapy of acute and chronic inflammation. ACS Nano. 2020;14(5):5862–5873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32379416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma B., Xu H., Wang Y., Yang L., Zhuang W., Li G., Wang Y. Biomimetic-coated nanoplatform with lipid-specific imaging and ROS responsiveness for atherosclerosis-targeted theranostics. ACS Appl. Mater. Interfaces. 2021;13(30):35410–35421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34286950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Namgung R., Mi Lee Y., Kim J., Jang Y., Lee B.H., Kim I.S., Sokkar P., Rhee Y.M., Hoffman A.S., Kim W.J. Poly-cyclodextrin and poly-paclitaxel nano-assembly for anticancer therapy. Nat. Commun. 2014;5:3702.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24805848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rhrl C., Stangl H. HDL endocytosis and resecretion. Biochim. Biophys. Acta. 2013;1831(11):1626–1633.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3795453</ArticleId>
            <ArticleId IdType="pubmed">23939397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu P., Sun Y., Wang Q., Sun Y., Li H., Duan Y. Intracellular trafficking and cellular uptake mechanism of mPEG-PLGA-PLL and mPEG-PLGA-PLL-Gal nanoparticles for targeted delivery to hepatomas. Biomaterials. 2014;35(2):760–770.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24148242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong J., Quinn C.M., Gelissen I.C., Jessup W., Brown A.J. The effect of statins on ABCA1 and ABCG1 expression in human macrophages is influenced by cellular cholesterol levels and extent of differentiation. Atherosclerosis. 2008;196(1):180–189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17466310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan H.-Y., Wang N., Li S., Hong M., Wang X., Feng Y.  2016. The Reactive Oxygen Species in Macrophage Polarization: Reflecting its Dual Role in Progression and Treatment of Human Diseases, Oxidative Medicine and Cellular Longevity 2016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4837277</ArticleId>
            <ArticleId IdType="pubmed">27143992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou F., Mei J., Yang S., Han X., Li H., Yu Z., Qiao H., Tang T. Modified ZIF-8 nanoparticles attenuate osteoarthritis by reprogramming the metabolic pathway of synovial macrophages. ACS Appl. Mater. Interfaces. 2019;12(2):2009–2022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31849213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang S.-F., Chang P.-Y., Chou Y.-C., Lu S.-C. Electronegative LDL induces M1 polarization of human macrophages through a LOX-1-dependent pathway. Inflammation. 2020;43(4):1524–1535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32394286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X., Wang S., Yao G., Yu D., Chen K., Tong Q., Ye L., Wu C., Sun Y., Li H. Identification of the histone lysine demethylase KDM4A/JMJD2A as a novel epigenetic target in M1 macrophage polarization induced by oxidized LDL. Oncotarget. 2017;8(70):114442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5777704</ArticleId>
            <ArticleId IdType="pubmed">29383092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rezaie-Majd A., Maca T., Bucek R.A., Valent P., Müller M.R., Husslein P., Kashanipour A., Minar E., Baghestanian M. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 2002;22(7):1194–1199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12117737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tuomisto T.T., Lumivuori H., Kansanen E., Häkkinen S.-K., Turunen M.P., Van Thienen J.V., Horrevoets A.J., Levonen A.-L., Ylä-Herttuala S. Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2. Cardiovasc. Res. 2008;78(1):175–184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18192240</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
